Oligonucleotide-based affinity chromatography methods
Patent Information
- Application Number
- JP2023527800
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-13
- Filing Date
- 2021-11-15
- Publication Date
- 2024-11-20
AI Technical Summary
Current purification methods for therapeutic mRNA, such as resin-based chromatography and anion exchange chromatography, face challenges with low binding capacity, long residence times, and suboptimal flow rates, which hinder high-throughput production and purification efficiency.
The development of oligo-dT-based affinity membrane chromatography using macroporous supports with oligonucleotide ligands, allowing for high dynamic binding capacity and rapid purification at flow rates up to 1000 CV/min, utilizing modified bases like LNA and PNA to enhance binding and reduce conductivity.
This method achieves 10 times higher productivity than resin-based methods, with rapid residence times as short as 0.06 seconds and high target recovery, enabling efficient purification of polynucleotides like mRNA.
Smart Images

Figure 00000012_0000 
Figure 00000013_0000 
Figure 00000013_0001
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 113,594, filed November 13, 2020, entitled “Use of Oligo-DT Based Affinity Membrane,” which is incorporated herein by whole reference. [Background technology]
[0002] Therapeutic mRNA has the potential to accelerate protein replacement therapy, address a wide variety of disease conditions, enhance vaccine safety, and shorten vaccine timelines, which is particularly important in pandemic scenarios. For example, Moderna® used its messenger ribonucleic acid (mRNA) platform for vaccines to develop the first clinical trial vaccine for Coronavirus Disease-19 (COVID-19) in the United States at record speed, moving from discovery to clinical trials in just three months. However, according to the CEO of CureVac, a pioneering company in mRNA-based drug development, the quality and quantity of mRNA—that is, consistent purity—remain obstacles to their production. In particular, the lack of high-throughput downstream purification processes is a major challenge in upscaling industrial mRNA production.
[0003] Examples of existing purification processes include chromatography used to purify mRNA produced from cell extracts, in vitro transcription (IVT) reactions, or other bioengineered or synthetic means. For proper purification, mRNA must be separated from proteins, nucleic acids, and / or other components from cells or culture media, as well as additives or solvents used in extractions from host cells. In purification from IVT reactions or other synthetic means, capping components, free nucleotides, enzymes such as T7 polymerase, RNase inhibitors (if present), template DNA, and any non-mRNA components and / or unpolyadenylated RNA must be removed during purification.
[0004] Resin chromatography columns containing a solid phase in the form of individual particles (or resin) have been used for scalable antibody production. However, therapeutic mRNA (300–1,000 kDa) is significantly larger than antibodies (approximately 150 kDa). For example, as illustrated in Figure 1, therapeutic mRNA typically has a 5–300 nucleotide polyadenylate (poly-A) tail, which, along with the untranslated region (UTR), cap, and coding region, is an essential component of the protein translation process. Due to such large size, the effective surface area and volume of the resin column are much lower for mRNA than for antibody purification.
[0005] Oligo-deoxythymidine (oligo-dT) ligands are recognized as effective affinity ligands for isolating polyadenylated mRNA from feed streams via hybridization after Watson-Crick base pairing between adenine in the poly-A tail and deoxythymidine in oligo-dT, as shown in Figure 2. While oligo-dT affinity-based resin chromatography products have been proposed, unfortunately, they are characterized by low to moderate binding capacities of 0.6–5 mg mRNA / mL resin for mRNAs in the 200–4,000 base length range. Furthermore, these resin products require long residence times (several minutes) to function effectively due to slow mass transfer into solid phase pores and poor flow characteristics of resin-based columns. In addition, resin-based columns are generally limited by maximum operational flow rates below 1 column volume (CV) / min. Resin bed compression and / or structural deformation also result in suboptimal performance and increased back pressure. In addition, the low to moderate binding capacity and long residence time of the resin column result in insufficient purification productivity.
[0006] Anion exchange chromatography products have also been proposed for mRNA purification. While anion exchange chromatography products can offer higher binding capacity compared to affinity-based systems, they are not very attractive alternatives because they make it very difficult to elute mRNA from the column in high yield.
[0007] Advection separation media such as monoliths and macroporous membranes have been shown to provide processing rates at least 10 times faster than resins for the purification of many biopharmaceuticals. For example, BIA Separations' monolith-based oligo-dT affinity column products moderately reduce residence times (recommended residence time is 12-48 seconds, with a minimum residence time of 3.3 seconds).
[0008] While improvements in this technical field have been described above, there is still room for further improvement. What is needed in this technical field are affinity-based membrane chromatography products for mRNA purification. For example, oligo-dT-based affinity membrane chromatography products for mRNA purification would bring significant benefits to this technical field. [Overview of the project] [Means for solving the problem]
[0009] According to one embodiment, a method for purifying polynucleotides, such as mRNA, DNA, etc., is disclosed. The method may include loading a feed solution containing the polynucleotide onto a chromatography medium. The chromatography medium may include a macroporous support, which may also contain an oligonucleotide affinity ligand on the surface of the macrosupport. The oligonucleotide affinity ligand may include a nucleotide sequence complementary to the nucleotide sequence of the polynucleotide. Thus, as the feed solution flows through the medium, the target polynucleotide can be retained via hybridization with the affinity ligand, and impurities in the feed solution can pass through the chromatography medium. The chromatography medium may exhibit a dynamic binding capacity of about 0.2 mg polynucleotide / mL to about 15 mg polynucleotide / mL, and the method can be performed at high flow rates, for example, about 0.5 column volumes (CV) / min to about 1000 CV / min. The method may also include recovering the polynucleotide after separation of the polynucleotide from the porous support, for example, after elution of the polynucleotide from the macroporous support.
[0010] A complete and effective disclosure of this subject matter, including the most optimal method for those skilled in the art, is described in more detail in the remainder of this specification, including references to the accompanying drawings. [Brief explanation of the drawing]
[0011] [Figure 1]A schematic diagram shows the structure of a typical mRNA encoding a human protein, including the cap, 5' untranslated region (UTR), coding region, 3'UTR, and poly-A3' tail. [Figure 2] This shows the hydrogen bond structure between adenine and thymine bases during hybridization. [Figure 3] This shows the mRNA dynamic binding capacity of the oligo-dT affinity membranes disclosed herein, which have different pore sizes, at 5 CV / min. [Figure 4] This shows the mRNA dynamic binding capacity of the oligo-dT affinity membranes disclosed herein at different flow rates up to 500 CV / min. [Figure 5] The purification yield for a 0.1 mL device at various flow rates via 80 CV / min is shown. [Figure 6] This shows the theoretical and relative loading process productivity (residence time in mg / min with up to 10% DBC binding) for various oligo-dT products. [Figure 7] We compare the 10% dynamic binding capacity (DBC10%) values of commercially available resin-based separation media at two different flow rates for two different mRNA targets. [Figure 8] This specification provides DBC 10% values for mRNA targets of different sizes at multiple different flow rates, obtained by the method described herein. [Figure 9] The results of a 20-cycle bind-and-elute test, including a clean-in-place protocol for determining the long-term binding capacity of the disclosed methodology, are shown. [Modes for carrying out the invention]
[0012] Various embodiments of the disclosed subject matter are described in detail here, one or more of which are given below. Each embodiment is provided for the purpose of describing the subject matter and is not limiting thereto. In fact, it will be apparent to those skilled in the art that various modifications and changes can be made in this disclosure without departing from the scope or spirit of the subject matter. For example, features exemplified or described as part of one embodiment may be used in another embodiment to bring about other further embodiments.
[0013] Unless otherwise specified, the terms and phrases used in this document, and their variations thereof, should be interpreted as open-ended and not restrictive unless explicitly indicated. Similarly, groups of items linked with the conjunction "and" should not be interpreted as requiring each or all of those items to be present in the group, but rather as "and / or" unless explicitly stated otherwise. Likewise, groups of items linked with the conjunction "or" should not be interpreted as requiring mutual exclusivity between the groups, but rather as "and / or" unless explicitly stated otherwise. Furthermore, items, elements, or components of this disclosure may be described or claimed in the singular, but unless explicitly limited to the singular, the plural is considered to be within their scope. The presence of broad words or phrases such as "one or more," "at least," "but not limited to these," or other similar phrases should not be interpreted as meaning that, in some cases, a narrower case in which such broad words or phrases do not exist is intended or required.
[0014] Generally, affinity-based chromatography processes utilizing separation devices containing oligonucleotide ligands on a porous support are disclosed herein. The disclosed methods can provide high binding capacity in polynucleotide purification performance, including high impurity clearance with low back pressure at flow rates of about 0.5 CV / min to about 1000 CV / min. The disclosed methods can advantageously provide complete target sequence recovery values of about 80% or more.
[0015] The disclosed method can be utilized to rapidly and efficiently purify polynucleotides using an oligonucleotide-based affinity medium. As an example, the disclosed method can successfully purify target polynucleotides at a flow rate of from about 0.5 CV / min to about 1000 CV / min. In one embodiment, the method can be performed at a flow rate of from about 0.5 CV / min to about 500 CV / min. In one embodiment, the method can be performed at a flow rate of from about 1 CV / min to about 1000 CV / min. In one embodiment, the method can be performed at a flow rate of from about 1 CV / min to about 500 CV / min. In one embodiment, the method can be performed at a flow rate of from about 5 CV / min to about 1000 CV / min. In one embodiment, the method can be performed at a flow rate of from about 5 CV / min to about 500 CV / min.
[0016] Devices for use in the disclosed method can include a macroporous membrane support material having an oligonucleotide affinity ligand thereon. In one embodiment, the disclosed method can utilize a macroporous oligonucleotide-based affinity medium as described in Zhou et al., U.S. Patent Application Publication No. 2020 / 0188859, which is hereby incorporated by reference in its entirety. As examples, macroporous supports can include, but are not limited to, polyolefin membranes, polyethersulfone membranes, poly(tetrafluoroethylene) membranes, nylon membranes, fiberglass membranes, hydrogel membranes, hydrogel monoliths, polyvinyl alcohol membranes, natural polymer membranes, cellulose membranes (e.g., cellulose ester membranes, cellulose acetate membranes, regenerated cellulose membranes, cellulose nanofiber membranes, cellulose monoliths, membranes substantially containing cellulose or its derivatives (e.g., about 90 wt% or more)), filter paper membranes, and combinations thereof.
[0017] The macroporous support may optionally be derivatized to present oligonucleotide affinity ligands on its surface via coupling groups containing either innate reactive sites or reactive sites bound to the membrane. For example, the macroporous support may be subjected to a multi-step derivatization process in which the membrane is immersed in a swelling solvent (e.g., dimethyl sulfoxide, acetonitrile, tetrahydrofuran, dimethylformamide, etc.) in combination with an activator (e.g., N,N'-disuccinimidyl carbonate) to add the reactive sites to the membrane. Subsequently, the reactive sites can react directly with the affinity ligands or optionally with an intermediate group (e.g., an intermediate group having further reactivity to affinity ligands, optionally accompanied by an alkyl chain as a spacer group as further described herein) to form a macroporous support for use as described herein. Naturally, other formation methods commonly known in the art may be used as alternatives to provide a macroporous support for use in the disclosed method. Generally, a macroporous support for use in the disclosed method may have a thickness of about 1 m 2 / mL ~ approx. 20m 2 It may include a specific surface area of / mL.
[0018] Generally, the method can utilize an oligonucleotide affinity ligand containing a sequence that is complementary to the target polynucleotide (e.g., about two or more individual sequences of the entire ligand). As is known in the art, the complementary portions of the affinity ligand and the target do not need to extend across both lengths, and portions of each can optionally hybridize with each discontinuous segment that hybridizes with each other. For example, in those embodiments, in which the affinity ligand contains a modified base (e.g., a PNA or LNA base as further described herein), the particular base does not have to hybridize with the target base, but the sequences of the bases on one or both sides of the modified base can hybridize with the base of the target polynucleotide. For example, a macroporous support can, in some embodiments, carry an oligonucleotide ligand portion that can bind to a targeted polynucleotide having a dynamic binding capacity of about 0.2 mg polynucleotide (e.g., RNA) / mL to about 15 mg polynucleotide / mL.
[0019] In one embodiment, the method can utilize oligo-dTs of about 5 to about 100 bases in length as affinity ligands, but in some embodiments, longer lengths may be used. For example, oligonucleotide affinity ligands immobilized on an affinity medium may be of about 5 to about 25 bases in length, such as about 5 to about 20 bases, about 10 to about 100 bases, about 10 to about 50 bases, about 10 to about 40 bases, about 10 to about 30 bases, about 10 to about 20 bases, about 20 to about 100 bases, about 20 to about 40 bases, about 20 to about 30 bases, etc., in some embodiments.
[0020] In some embodiments, the spacer may be covalently bonded between a macroporous support and an oligonucleotide affinity ligand. Generally, the spacer may comprise a carbon monomer or oligomer. For example, the spacer may comprise a carbon monomer (e.g., -CH2-) or a carbon oligomer having a chain length of up to about 50 carbon atoms. For example, in some embodiments, the spacer may have a chain length of up to about 20 carbons or up to about 10 carbons. In one embodiment, the carbon spacer may have a chain length of about 5 to about 50 carbons, such as about 5 to about 20 carbons or about 5 to about 10 carbons.
[0021] In one embodiment, the affinity ligand may contain one or more base substitutions compared to the native bases of a sequence complementary to the target polynucleotide, which can alter the performance of the ligand. One such modification is the use of locked nucleic acid (LNA) bases. LNA is a modified RNA base having a covalent bond linking the 2' oxygen and 4' carbon on a ribose sugar.
[0022] In one embodiment, peptide nucleic acid (PNA) ligands can be used as affinity ligands. PNA utilizes peptide bonds to bind bases without a negatively charged backbone. In addition to this affinity-enhancing configuration, the absence of a negative charge on the ligand allows binding and purification processes to be carried out with feeds that exhibit little conductivity.
[0023] Base modifications can be used as substitutions for one or more nucleotides of an affinity ligand. Such modifications can further enhance the interaction between the affinity ligand and the target nucleotide, allowing for the use of higher flow rates to improve chromatographic productivity. In one embodiment, the affinity ligand may contain a single modified base. In other embodiments, the affinity ligand may contain multiple modified bases. For example, the affinity ligand may contain an LNA or PNA base at every second, third, fourth, or fifth position of the affinity ligand. Furthermore, there may be discontinuous tracts of modified bases interspersed with native bases, for example, tracts of three LNA or PNA alternating with tracts of three native bases, but the tracts do not need to be evenly balanced or regularly spaced, for example, tracts of three LNA or PNA alternating with tracts of five native bases, or a repeat of 3 LNA or PNA tracts followed by 5 native bases, followed by 2 LNA or PNA, followed by 7 native bases. Furthermore, the base substitutions may be of the same type or of different types. For example, an affinity ligand may contain multiple base substitutions such that all base substitutions are LNA bases or PNA bases, or the multiple base substitutions may contain a mixture of both LNA bases and PNA bases in any combination. In other embodiments, only one type of substitution may be included in the affinity ligand modified from the complementary sequence of the conventional unmodified base target molecule, for example, one or more LNA substitutions only, one or more PNA substitutions only, or one substitution of a native base for a modified base, examples of which are further provided below.
[0024] In some embodiments, base modification enables binding at potentially reduced conductivity, reducing the need for extensive post-binding washing steps and further improving the processing speed of purification protocols. For example, oligonucleotide ligands containing complete PNA substitution can maintain hybridization properties at conductivity less than 1.5 mS / cm. Base modification can, in some embodiments, promote better complementary base recognition, which can provide opportunities for novel nucleic acid isolation techniques such as isolation of single-base substitution variants or targeted purification of sequences without polyadenylation. Naturally, complete PNA or LNA base substitution of oligonucleotide affinity ligands is not mandatory; base substitutions may be absent for the bases of the oligonucleotide affinity ligand, or present at one or more bases. In one embodiment, affinity ligands containing partial or complete LNA or PNA substitutions for individual bases of the oligonucleotide ligand can increase the possibility of targeted purification of double-stranded nucleic acids resulting from triple-strand formation between the oligonucleotide ligand and the target via Hoogsteen-type hydrogen bonding interactions.
[0025] Modifications included herein are not limited to PNA and / or LNA base substitutions. For example, base modifications include, but are not limited to, 5-iodocytidine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 2-thiocytidine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, pseudoisocytidine-5'-triphosphate, N 4-Methylcytidine-5'-triphosphate, 5-carboxycytidine-5'-triphosphate, 5-formylcytidine-5'-triphosphate, 5-hydroxymethylcytidine-5'-triphosphate, 5-hydroxycytidine-5'-triphosphate, 5-methoxycytidine-5'-triphosphate, thienocytidine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-methyl-2'-deoxycytidine-5'-triphosphate, 2'-deoxy-P-nucleoside-5'-triphosphate, 5-hydroxy-2'-deoxycytidine-5'-triphosphate, 2-thio-2'-deoxycytidine-5'-triphosphate, 5-aminoallyl-2'-deoxycytidine-5'-triphosphate, pseudouridine-5'-triphosphate, 2'-O-methylpseudouridine-5'-triphosphate, N 1 -Methylpseudouridine-5'-triphosphate, N 1 -Ethylpseudouridine-5'-triphosphate, N 1 -Methyl-2'-O-methylpseudouridine-5'-triphosphate, N 1 -Methoxymethylpseudouridine-5'-triphosphate, or N 1 -Propylpseudouridine-5'-triphosphate may include a base substitution for the cytidine or uridine base of the oligonucleotide affinity ligand that includes one or more of the above.
[0026] The oligonucleotide ligand-based affinity membrane column utilized in the disclosed methodology can operate in either a binding-elution mode or a flow-through mode.
[0027] The process productivity of the separation can be defined using the following equation. In the equation, V tot`BV` represents the total volume of solution passing through the column during the separation protocol, which includes loading, rinsing, elution, and regeneration steps. `BV` represents the oligonucleotide medium bed volume. The loading volume can be proportional to the dynamic binding capacity of the oligonucleotide medium. Therefore, process productivity can be increased with increasing binding capacity and decreasing residence time.
number
[0028] The disclosed method can provide more than 10 times higher productivity compared to existing resin chromatography-based methods. For example, as shown in Figure 6, the method disclosed herein (as shown by the use of membranes 1, 2, and 3 in Figure 6) can provide higher binding capacity with very short residence times, significantly improving productivity compared to methods utilizing previously known resin-based separation materials. Furthermore, the oligonucleotide ligand-based affinity chromatography for polynucleotide purification disclosed herein can operate at flow rates of 0.5 CV / min to 1000 CV / min in some embodiments, while current oligo-dT resin column products operate at flow rates of less than 1 CV / min. For example, current oligo-dT resin column products may require a residence time of 360 seconds, whereas the disclosed method can be performed with very fast residence times, as shown in Figure 6. In some embodiments, oligonucleotide ligand-based affinity chromatography for polynucleotide purification, as described herein, can effectively operate with short residence times of about 0.06 seconds.
[0029] The size (i.e., internal volume) of the separation device for the disclosed method is not particularly limited. Generally, a preferred device size can be selected based on the scale of the preparation, and different device sizes are used for preparations of different scales. Thus, the volume of the macroporous support of the separation protocol can also vary. In one embodiment, the volume of the macroporous support may be about 0.025 mL to about 100 liters, such as about 0.2 mL to about 5 mL, about 1 mL to about 100 mL, about 100 mL to about 1 liter, about 0.2 mL to about 1 liter, about 0.2 mL to about 10 liters, about 1 liter to about 10 liters, about 10 liters to about 100 liters, etc.
[0030] Oligonucleotide affinity-based purification processes, such as those disclosed herein, may generally comprise several steps. One step of the protocol may include loading a feed containing polynucleotides for separation onto a chromatographic medium, which may include a macroporous support. The feed supplied to the chromatographic medium may be conductive in some embodiments. For example, in one embodiment, if the affinity ligand incorporates one or more base substitutions (e.g., LNA and / or PNA substitutions), the conductivity of the feed may be up to about 3.35 mS / cm, or in some embodiments, even higher. In one embodiment, the conductivity of the feed may be between 0 and 3.35 mS / cm, such as about 1.5 to about 3.35 mS / cm. As previously stated, substitution of at least one oligonucleotide affinity ligand to an LNA base and / or a PNA base can be used to improve aspects of the separation protocol when considering a conductive feed.
[0031] The targeted polynucleotide in the supply solution may have any structure or base content. In one embodiment, the purified target may be single-stranded RNA or DNA. Although not required, in one embodiment, the purified target may be double-stranded DNA, double-stranded RNA, hybridized DNA / RNA double helix, DNA / peptide conjugate, RNA / peptide conjugate, DNA / polypeptide conjugate, or RNA / polypeptide conjugate. In one embodiment, the targeted polynucleotide may have a size of about 300 to about 5,000 bases. For example, the targeted polynucleotide may be single-stranded or double-stranded RNA or DNA of approximately 800 bases / base pair (in the case of double-stranded RNA) or longer, such as approximately 500 bases / base pair to approximately 15,000 bases / base pair in some embodiments, approximately 1,000 bases / base pair to approximately 12,000 bases / base pair in some embodiments, approximately 4,000 bases / base pair to approximately 10,000 bases / base pair, approximately 800 bases / base pair to approximately 4,000 bases / base pair, or approximately 10,000 bases / base pair to approximately 15,000 bases / base pair in some embodiments, but longer and shorter targeted polynucleotides are included herein.
[0032] Other properties of the feed solution are not particularly limited. In one embodiment, the pH of the feed solution may be in the range of about 1 to about 8.5. In one embodiment, the pH of the feed solution may be in the range of about 6 to about 10. In some embodiments, a high pH feed solution can be used in protocols targeting DNA, and in some embodiments, a lower pH feed solution can be used in protocols targeting RNA, but this is not a requirement of the disclosed methodology.
[0033] In some embodiments, the separation protocol may include a washing step after the coupling step and before elution. For example, the washing step may be used to wash one or more impurities from the medium before elution. In one embodiment, the washing step may utilize a washing fluid that exhibits conductivity (for example, by adding one or more suitable salts as known in the art). In such embodiments, conductive washing (e.g., high salt content) may be used in a protocol that includes a low-conductivity or non-conductivity feed solution during the coupling step, or in a relatively high-conductivity feed solution, i.e., in a high-conductivity coupling. For example, the conductivity of the fluid used in the washing step may range from a non-conductivity washing solution to about 3.35 mS / cm in some embodiments. For example, the fluid used in the washing step may exhibit a conductivity essentially the same as (e.g., within a range of about 10% or less) as that of the conductive or non-conductive supply flow, or it may exhibit a different conductivity than that of the supply flow. For example, in some embodiments, the washing fluid may exhibit a conductivity different from that of the supply flow, such as about 1.5 mS / cm or less, or about 3.35 mS / cm, such as about 1.5 to about 3.35 mS / cm. Naturally, the washing step is not a requirement of the disclosed protocol, and in one embodiment, it is not necessary to perform the washing step under non-loading buffer conditions. For example, in embodiments where the oligonucleotide affinity ligand contains one or more PNA base substitutions in the ligand, it may not be necessary or desirable to perform the washing step under non-loading buffer conditions.
[0034] The separation protocol may include a step of eluting the targeted polynucleotide from the chromatographic medium. The eluent may be used in the disclosed methods as is known in the art, and these may include, but are not limited to, water (e.g., deionized water, RNase-free water) and tris(hydroxymethyl)aminomethane hydrochloride (tris-HCl) (e.g., 10 mM tris-HCl pH 7.0-7.5, generally RNase-free).
[0035] Generally, elution of targeted polynucleotides can be performed after impurities have been significantly separated from the polynucleotides. In one embodiment, the eluent may exhibit conductivity. For example, the eluent may exhibit conductivity of about 1.5 mS / cm or less, such as 0 to about 1.5 mS / cm. In one embodiment, the temperature of the eluent may be ambient temperature (i.e., room temperature or about 25°C) to about 90°C, such as about 25°C to about 65°C, or about 15°C to about 90°C. In one embodiment, the eluent may have a temperature above about 40°C. For example, a high-temperature eluent may be used in one embodiment in which the oligonucleotide affinity ligand contains one or more PNA bases on the ligand. Generally, the pressure on the separation medium throughout the separation protocol (e.g., transmembrane pressure or transcolumn pressure) may be about 1 MPa or less, such as about 0.5 MPa or less, in some embodiments.
[0036] The disclosed isolation protocol can provide high-flow, high-capacity binding for the purification of polynucleotides of any size. Furthermore, the disclosed isolation protocol can provide long-term binding capacity, with the binding capacity maintained at values of approximately 80% or more, approximately 85% or more, approximately 90% or more, approximately 95% or more, approximately 96% or more, or 97% or more over multiple binding-elution cycles, for example, over 20 binding-elution cycles, over 50 binding-elution cycles, or over 100 binding-elution cycles in some embodiments.
[0037] This disclosure can be better understood by referring to the examples described below. [Examples]
[0038] Example 1 The mRNA dynamic binding capacity of oligo-dT-based affinity membrane columns was investigated. In this example, the 10% dynamic binding capacity value (DBC) was determined. 10% ) was decided. DBC 10% This represents the mass of the target bound per unit volume of the chromatography medium when the target concentration in the eluent from the membrane bed reaches 10% of the target concentration in the feed solution.
[0039] Figure 3 shows the DBC of oligo-dT-based membrane columns using membranes with three different pore sizes. 10% This shows that the membrane was formed according to the method described in U.S. Patent Application Publication No. 2020 / 0188859, which is incorporated herein by prior reference. Briefly, the membrane contained a 25-nucleotide oligo-dT affinity ligand and included a 6C spacer between the macroporous matrix and the oligo-dT affinity ligand. The nominal pore sizes of the three membrane columns were 0.2 μm, 0.45 μm, and 1.0 μm. The targeted mRNA was green fluorescent protein (GFP) mRNA with approximately 800 nucleotides and a poly-A tail. The mRNA was dissolved in a feed solution of 50 mM phosphate, 250 mM NaCl, pH 7.0 buffer. The mRNA concentration in the feed solution was 0.1 mg / mL. The loading flow rate was fixed at 5 CV / min, representing a residence time of 12 seconds. The test was performed at room temperature. DBC as shown in Figure 3. 10% This is higher with membrane columns having smaller pores, DBC 10% As shown, the value reached a level exceeding 10 mg / mL.
[0040] Example 2 The effect of flow rate on the mRNA dynamic binding capacity of an oligo-dT-based affinity membrane column was investigated. The separation medium was as described in Example 1 above.
[0041] Figure 4 shows the 10% dynamic binding capacity (DBC) of oligo-dT-based chromatography media at various flow rates. 10% The feed solution provided was 0.1 mg / mL of GFP mRNA in 50 mM phosphate, 250 mM NaCl, and pH 7.0. The residence time is inversely proportional to the flow rate for a given chromatography column. In this example, the residence time varied from 12 seconds to 0.12 seconds, which corresponds to flow rates of 5 CV / min to 500 CV / min for the relatively small volume column used (Figure 4). As shown in the figure, DBC 10% This was slightly affected by the flow rate relative to a given floor volume.
[0042] Figure 5 shows the yield % (mg of injected mRNA / mg of mRNA recovered in eluent) for a 0.1 mL device using a 0.45 μm pore diameter macroporous support containing a 25-base oligo-dT with six carbon spacers between the prepared macroporous matrix and affinity ligand, as described above. As shown in the figure, the yield was consistent for flow rates of at least 80 CV / min.
[0043] Figure 6 includes theoretical loading process productivity (mg / min of mRNA) for the product reported in the literature, as well as data collected using a 0.2 mL device operating at 5 CV / min, incorporating a macroporous membrane separation medium functionalized with a 25-base oligo-dT having a 6C spacer, with pore sizes of 0.2 μm, 0.45 μm, or 1.0 μm as described. As shown, the loading process productivity of the disclosed method can exceed the performance of previously known methods utilizing resin-based separation materials at 1 / 200 of the operable rate.
[0044] Example 3 The binding capacity of targeted mRNA was investigated for targets of different sizes and different isolation media. The materials examined included a commercially available product (POROS®-OdT resin) and a porous membrane medium with a pore size of 0.45 μm, functionalized with a 25-nucleotide oligo-dT affinity ligand and mounted on a macroporous membrane via a 6C spacer. Targeted mRNAs included 4000-nucleotide and 800-nucleotide mRNAs. The feed solution contained one of the targeted mRNAs at 0.1 mg / mL in 50 mM phosphate, 250 mM NaCl, pH 7.0.
[0045] The commercially available product is recommended for use at a flow rate of 0.25 CV / min. The isolation protocol was performed using this commercially available product for both mRNA targets at the recommended flow rate of 0.25 CV / min, as well as at a higher flow rate of 1 CV / min. The results are shown in Figure 7. As shown, the binding capacity for 4000 nucleotide mRNA was 32% lower at the recommended flow rate of 0.25 CV / min than for 800 nucleotide mRNA. Increasing the flow rate beyond the recommended limit resulted in a 38% decrease in capacity for 800 nucleotide mRNA and a 66% decrease for 4000 nucleotide mRNA.
[0046] Membrane-based separation materials were investigated for the separation of two different sizes of mRNA and at multiple flow rates from 10 CV / min to 80 CV / min. The results are shown in Figure 8. As shown, the binding capacity for 4,000 nucleotide mRNA was only 7% lower than that for 800 nucleotide mRNA. Furthermore, from the lowest to the highest flow rates (10–80 CV / min), the 800 nucleotide mRNA protocol showed only a 20% decrease in capacity, while the 4,000 nucleotide mRNA protocol showed a 26% decrease.
[0047] The purification protocol was 10 to 160 times faster using the disclosed methodology compared to resin-based separation protocols under the manufacturer's recommended conditions. Furthermore, the disclosed method resulted in a target recovery rate of 93% to 96%. The disclosed methodology exhibits more robust performance compared to resin-based methods, particularly when considering the purification of large volumes of mRNA targets.
[0048] Example 4 The in-situ cleaning protocol was performed on the membrane separation device of Example 4 using 0.1 M NaOH and a contact time of 5 minutes. The protocol was performed for 20 binding elution cycles. Figure 9 shows the results, indicating that the binding capacity of the device was maintained at an average of 98% over the 20 cycle test, with the lowest value determined throughout the test being 96.5%.
[0049] While the subject matter of the present invention has been described in detail with respect to certain exemplary embodiments and methods thereof, it will be understood by those skilled in the art that, having grasped the foregoing, modifications, variations, and equivalents can easily be made to such embodiments. Therefore, the scope of this disclosure is not limiting and is exemplary, and the disclosure of subject matter does not preclude modifications, variations, and / or additions to the subject matter of the present invention, as will be readily apparent to those skilled in the art using the teachings disclosed herein.
Claims
1. A chromatography medium comprising: a membrane macroporous support substrate, the membrane macroporous support having a specific surface area of 1 m 2 / mL to 20 m 2 / mL; an affinity ligand comprising an oligo-deoxythymidine sequence containing from 5 to 100 bases.
2. The chromatography medium of claim 1, wherein the macroporous support of the membrane comprises cellulose acetate, regenerated cellulose, cellulose nanofibers, or the macroporous support of the membrane comprises 90% or more by weight of cellulose.
3. The chromatography medium of claim 1, further comprising a carbon spacer covalently bonding the affinity ligand to the macroporous support substrate of the membrane.
4. A chromatography medium described in any one of claims 1 to 3, wherein the chromatography medium has a dynamic binding capacity of 0.2 mg polynucleotide / mL to 15 mg polynucleotide / mL.
5. A chromatography medium described in any one of claims 1 to 4, wherein the oligo-deoxythymidine sequence comprises one or more base substitutions, the one or more base substitutions comprising one or more locked nucleic acid bases and / or one or more peptide nucleic acid bases.
